MI-PANGEA
24.5.2023 15:31:26 CEST | Business Wire | Press release
Pangea commits to becoming the world’s most trusted, sustainable automotive leather supplier, hitting major targets including LWG Gold certification and publication of an inaugural Sustainability Report. The company announces all manufacturing sites are now certified sustainable by the LWG Gold standard. Most recently, the teams were awarded the highest available standard in South Africa and Germany.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230524005545/en/
Pangea - Automotive Leather (Photo: Business Wire)
Sustainability reporting and auditing has helped Pangea better understand its organization at an even deeper level than standard automotive audits like ISO and IATF.
“This process has helped us better understand who we are and how we operate. It genuinely resonates with the oneness and standardization themes our brand exudes. Proper execution and year-over-year improvement has helped us strengthen our market leadership, guiding the industry to an even stronger image and material market share.” – Roger Pinto, Director of Sustainability & Innovation
The audit preparation for LWG was new for many of Pangea’s business units. Executives and plant managers alike encouraged teams to focus on sustainable reporting initiatives in 2023, especially LWG. The efforts displayed showed determination, unity, and a corporate commitment to sustainable manufacturing, resulting in nothing short of a mass-scale learning experience.
Sustainability is in focus worldwide and across all industries, naturally becoming important for a global automotive materials manufacturer like Pangea. LWG was founded by leather customers who understand how bio-based operations can truly improve the planet, outlining organizational performance. Commitment to sustainability is a customer priority; and an initiative Pangea chose to embrace. Establishing all sites as gold-certified means the supplier commits to a well-rounded sustainable audit and promises continuous improvement.
“The need to report our sustainable goals and progress was driven by our commitment to not only remain competitive, but to lead the industry in trust, service, and passion for natural leather.” – Randy Johnson, President & CEO
The company’s biggest focus for the next two years will be energy management. As one of the most important sections to LWG, it is also tied to lowering scope 1+2 emissions, ISO 50001 certification, and life cycle assessment (LCA) results. Site based solar projects are a priority, with various sites already operational, and plans for further renewable energy in place. Pangea expects to obtain an annualized 2-3% global energy efficiency by 2025, as well as a 16% reduction of freshwater intake.
To check out Pangea’s sustainability report, click here.
About Pangea
Pangea is a global leather supplier to the world’s leading automotive brands, providing sustainable solutions that drive the future of interiors. Headquartered in Rochester Hills, Michigan, Pangea serves its customers on four continents with nearly 3,500 team members. For more information, visit www.pangeamade.com, and follow us on LinkedIn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230524005545/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
